SS Innovations Unveils Cutting-Edge Robotic Cardiac Surgery Program in India

 

SS Innovations Unveils Cutting-Edge Robotic Cardiac Surgery Program in India

SS Innovations International, Inc. (referred to as "SS Innovations") (OTC: SSII), a pioneering developer of cutting-edge surgical robotic technologies, is proud to announce the launch of an innovative robotic cardiac surgery program in India, utilizing its flagship SSi Mantra surgical robotic system.

This initiative by SS Innovations aims to reinvigorate the field of robotic coronary artery bypass and intracardiac surgery in India while training surgeons across the country in these advanced procedures using the SSi Mantra system. To date, over 20 successful robotic cardiac surgeries have been conducted in India with SS Innovations' surgical robotic technology.

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, expressed, "Every year, more than 2 million open heart surgeries are performed worldwide. In contrast, India carries out approximately 100,000 of these surgeries annually. Shockingly, over 95% of global patients still undergo maximally invasive heart surgeries that require sternum splitting, resulting in higher blood loss, heightened risk of wound infections, and prolonged patient recoveries."

Drawing from his extensive experience in the United States, Dr. Srivastava added, "I have been part of groundbreaking cardiac bypass procedures in the USA, which avoided such invasive approaches. Most of my cardiac bypass patients there returned home within three days or less. We must harness technology to its full potential. My vision was always to revive robotic cardiac surgery, and in developing the Mantra Surgical Robotic System, I ensured that cardiac surgery remains a viable treatment option for patients globally. Every patient should have access to gold standard surgical care, and we believe our cost-effective surgical robotic system plays a pivotal role in achieving this."

SS Innovations plans to roll out multiple robotic cardiac surgical programs across India, with future international expansions on the horizon. Collaborating with global leaders in cardiac surgery as part of their International Cardiac Advisory Board, SS Innovations aims to address the significant unmet need for safe, affordable, and timely cardiac surgical care worldwide.

In a remarkable milestone achieved in June 2023, Dr. Srivastava, a renowned cardiac surgeon, successfully performed the world's first beating heart robotic cardiac bypass surgery using the SSi Mantra. The Beating Heart Totally Endoscopic Coronary Artery Bypass (TECAB) procedure, one of the most intricate cardiac surgeries, is minimally invasive and performed on a beating heart, utilizing tiny ports within a closed chest, without the need for a cardiopulmonary bypass machine.

Dr. Srivastava's expertise extends to over 1,400 robotic cardiothoracic surgical procedures, including an impressive 750 TECAB cases.

The SSi Mantra Surgical Robotic System is India's first indigenous surgical system and one of the few globally recognized for its cost-effectiveness and versatile surgical applications, including cardiac surgery. It has received regulatory approval in India and is clinically validated for over 40 different surgical procedures. SS Innovations anticipates securing regulatory approvals in the United States and Europe in 2024 and 2025.

About SS Innovations International, Inc.

SS Innovations International, Inc. (OTC: SSII) is a trailblazing developer of innovative surgical robotic technologies with a mission to make the benefits of robotic surgery accessible and affordable to a wider global population. Their product lineup includes the proprietary "SSi Mantra" surgical robotic system and "SSi Mudra," a comprehensive range of surgical instruments supporting various surgical procedures, including robotic cardiac surgery. With its headquarters in India, SS Innovations aims to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions worldwide. For more information, visit SS Innovations' website at ssinnovations.com or follow them on LinkedIn for updates.

About SSi Mantra

Empowering advanced, affordable, and accessible robotic surgery, the SSi Mantra Surgical Robotic System is equipped for multi-specialty usage, covering cardiothoracic, head and neck, gynecology, urology, general surgery, and more. Featuring a modular design with 3D vision open-console and superior ergonomics, the system employs machine learning models to enhance safety and efficiency during procedures. The SSi Mantra system has secured Indian Medical Device regulatory approval (CDSCO) and has been clinically validated in India for over 40 different surgical procedures. The company anticipates seeking regulatory approvals from the US Food and Drug Administration (FDA) and CE Mark in Europe in 2023 and 2024.

Forward-Looking Statements

This press release may contain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are considered forward-looking, with terms such as "anticipate," "assume," "believe," "estimate," "expect," "intend," "may," "plan," "project," "potential," "target," and others. These statements relate to future events or the future financial performance of SS Innovations International and may involve known and unknown risks, uncertainties, and factors that could cause actual results to differ materially from future results expressed or implied by these forward-looking statements.